This study is in progress, not accepting new patients
A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedestimated completion
- Principal Investigator
- by Thomas Martin
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Lead Scientist at UCSF
- Thomas Martin
Professor, Medicine. Authored (or co-authored) 49 research publications.
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Janssen Research & Development, LLC
- ID
- NCT03548207
- Phase
- Phase 1/2
- Study Type
- Interventional
- Last Updated